(Q43542367)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11248608%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

title

Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11248608%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11248608%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

author name string

P Van Kerrebroeck

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11248608%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

U Jonas

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11248608%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

N Zinner

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11248608%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

A Wein

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11248608%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

Tolterodine Study Group

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11248608%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

language of work or name

English

0 references

publication date

1 March 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11248608%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11248608%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

volume

57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11248608%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11248608%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

page(s)

414-421

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11248608%20AND%20SRC:MED&resulttype=core&format=json

The overactive bladder: pharmacologic basis of drug treatment

5 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901113-4

7 January 2021

Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901113-4

7 January 2021

Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901113-4

7 January 2021

Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901113-4

7 January 2021

Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901113-4

7 January 2021

Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901113-4

7 January 2021

Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901113-4

7 January 2021

Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901113-4

7 January 2021

A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901113-4

7 January 2021

Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901113-4

7 January 2021

Muscarinic receptor antagonists in the treatment of overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901113-4

7 January 2021

Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901113-4

7 January 2021

Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901113-4

7 January 2021

Explicit criteria for determining potentially inappropriate medication use by the elderly. An update

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2901113-4

7 January 2021

10.1016/S0090-4295(00)01113-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11248608%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference